INTRODUCTION
MicroRNAs (miRNAs) are a class of short endogenous non-coding RNAs that act as key regulators of cell proliferation and apoptosis through control of expression of genes either inhibiting translation or triggering degradation of multiple target mRNAs. 1 miRNAs have been found to be deregulated in different malignancies, implicating them as oncogenes or tumor suppressors, and thus considered as promising new therapeutic targets for cancers. 2, 3 Indeed, selective induction of cell death by oligonucleotide-based drugs is a challenging goal for a rationale approach to novel therapeutic strategies in cancer treatment.
Programmed cell death, or apoptosis, is mediated through two major pathways, the death receptor pathway and the mitochondrial pathway. In the death receptor pathway, stimulation of death receptors leads to the formation of a death-inducing signaling complex, which includes initiator caspases such as caspase-8 that drive their activation through self-cleavage and then activate several downstream effectors, including caspase-9 and the ultimate effector caspase-3. 4 In the mitochondrial pathway, stimuli such as drugs, radiation, infectious agents and reactive oxygen species transmit the death signals to mitochondria through activation of BID, a pro-apoptotic member of the Bcl-2 family. 5 Caspase-8-mediated cleavage of BID thus provides integration of the death receptor with the mitochondrial pathway.
Identifying miRNAs that selectively regulate the expression of proteins involved in apoptosis could be helpful in the development of new tools for diagnosis and treatment of cancer. However, the potential for combinatorial regulation of gene expression by miRNAs makes it difficult to understand which are the targets involved and what are their coordinate mechanisms of action. 6 Therefore, as an alternative to high-throughput screening, here we developed a functional selection-based screening to identify those miRNAs that are able to rescue cells from apoptosis in lung cancer cells. This approach has the advantage to identify unique functional combinations of miRNA molecules without any assumption about the targets involved. As caspase-8 activation is a pivotal upstream event in the death receptor pathway, the screening has been based on the use of an engineered lung cancer cell line in which activation of caspase-8 has been placed under the control of the dimerizing agent AP20187. Here we show that this is an unbiased approach able to uncover unpredicted effects of miRNA expression. Indeed, miR-34c, a p53 effector miRNA, 7, 8 was shown to be able to antagonize paclitaxel-induced apoptosis, with obvious fall-outs in the design of miRNA-based new therapeutic agents for cancer treatment.
RESULTS

Identification of protective miRNAs by functional selection
In order to identify miRNAs able to rescue cells from caspase-8-induced cell death, we adopted a functional selection screening based on an FKBP caspase-8-inducible chimera (puro-DD-FKC8). 9, 10 Human non-small cell lung cancer (NSCLC) A549 cells were transduced with a retroviral vector with the caspase-8 chimera inserted. The most responsive cell clone, the A549-FK, was then transduced with a pooled miRNA library and subjected to selection for resistance to caspase-8 induction of cell death, as described in Supplementary Figure S1a.
Out of 16 cell clones analyzed, we found integrated miRNAs (see Supplementary information for more details) already described as oncogenic such as miR-17, miR-135 11 and miR-520. 12 However, we also found some miRNAs such as miR-124-1 and miR-34c for which a tumor-suppressive role has instead been described or expected. The most frequent integrated miRNA was miR-34c, which was also the only miRNA that was found not only in combination with other miRNAs, but also alone in two independent cell clones, thus suggesting to be sufficient by itself to confer resistance to caspase-8 activation (Supplementary Figure  S1b) . The other miRNAs were always found to be present as a combination of at least two different molecules (not shown). By quantitative reverse transcription --PCR (qt-RT --PCR) we thus evaluated in all cell clones the expression levels of transduced miRNAs (as compared with non-transduced, control cells) and assessed that, with the exception of only miR-645 in the clone Cl-Y (see Supplementary information), all transduced miRNAs are expressed in the corresponding surviving clones (not shown). In the case of miR-34c, the expression levels of both -5p and -3p strands were analyzed (see Supplementary Figure S1c ).
miR-34c-5p protects cells from capase-8-induced apoptosis Given the high frequency of integration of miR-34c in the surviving clones, we wondered if, in our system, forced overexpression of the most expressed isoform, miR-34c-5p, might protect cells from caspase-8-induced apoptosis. As determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-dipheniltetrazolium bromide) assay (Figure 1a ), all clones transduced with miR-34c are resistant to 10 nM AP20187 regardless of whether it was present alone (in two clones, Cl-T; Cl-8) or in combination with other miRNAs (in clones Cl-H; Cl-K; Cl-Y; Cl-1; Cl-2; Cl-12; Cl-17; Cl-53) (see legend to Supplementary Figure S1c ). In A549-FK cells, caspase-8 dimerization activates caspase-3 ( Figure 1b , lanes 1--3) through cleavage of the BH3-only protein BID (Figure 1c) , which leads to activation of Bax ( Figure 1d ) and caspase-9 ( Figure 1b , middle panel). In contrast to parental A549-FK, both cell clones analyzed (Cl-T and Cl-K), in which miR-34c was integrated either alone (Cl-T) or together with miR-124-1 and miR-362 (Cl-K), were resistant to AP20187-induced apoptosis (Figures 1b--d) . Resistance is unlikely due to occurrence of new clonal mutations impairing caspases that are indeed activated following cisplatin treatment (Figure 1e ). Conversely, transfecting cell clones with an miR-34c-5p inhibitor sensitizes cells to AP20187-induced cell death, with consequent increase of caspase-3 and caspase-9 activity in both Cl-T ( Figure 1f ) and in Cl-K (not shown). Further, upon AP20187 treatment, the presence of miR-34c-5p, but not of miR-34c-3p (not shown), makes the cells more resistant to caspase-8-induced cell death, reducing the percentage of apoptotic cells from 70% (of scrambled control) to about 30% (Figure 2a) . Consistently, resistance to apoptosis conferred by miR-34c-5p is accompanied by lack of activation of caspase-9 and its effector, caspase-3, with an increase in overall cell survival (Figures 2b--d) . These data indicate that, whereas in a proliferating cell population miR-34c-5p may induce an increase in apoptosis, 7, 8 in the presence of a strong acute pro-apoptotic signal, such as dimerization of caspase-8, it may, by contrast, elicit a clear protective effect. miR-34c-5p protects cells from paclitaxel-induced apoptosis We thus determined whether miR-34c-5p has an anti-apoptotic function toward broadly used chemotherapeutic agents. As shown in Figure 3a , treating parental A549 cells with 100 nM paclitaxel for 24 h induces caspase-3 and caspase-9 activation, which were partially reverted by transfecting cells with an miR-34c-5p mimic (left panel) but not with an miR-34c-3p mimic (right panel). Consistently, transfecting miR-34c-5p in A549 induces a clear reduction in the percentage of paclitaxel-induced apoptosis (Figure 3b ). On the other hand, upon antagonizing with the specific LNA (locked nucleic acid)-based miR inhibitor, miR-34c-5p, but not miR-34c-3p, rescued the sensitivity to paclitaxel-induced apoptosis in Cl-K cells (Figure 3c) . A similar protective effect against paclitaxel is elicited by miR-34c in A549-FK, but not in the more sensitive H460 NSCLC cells (not shown). Further, differently from what is observed with paclitaxel, transfecting an miR-34c-5p mimic does not reduce the levels of active caspase-3 and caspase-9 upon either TRAIL (200 ng/ml) or cisplatin (50 mg/ml) treatment. However, at least in transient, miR-34c-5p may cooperate with cisplatin (Figures 3d--e) . Taken together, these results well support the notion that the protective potential of miR-34c may be only unveiled in a cell context-and pathway-specific manner.
Targets of miR-34c-5p
In an attempt to understand the molecular events elicited by the effects of high levels of miR-34c-5p on apoptosis, and thus the target proteins that are involved, we first used a small antibody array to analyze the relative expression of a selected number of apoptosis-related proteins in A549-FK cells transfected with miR-34c-5p (not shown). As, using this assay, no major changes were observed, we thus decided to take advantage of the information emerging from the functional screening by assuming that the pathways involved may be shared between the different miRNAs selected for their ability to rescue A549-FK cells from caspase-8 DD-FKC8 chimera-induced cell death. We thus combined the bioinformatic prediction (Diana-microT 3 ) for targets common to those miRNAs transduced and expressed in three independent cell clones together with miR-34c, that is, in Cl-17 (miR-345 and miR-362), Cl-K (miR-362 and miR-124-1) and Cl-Y (miR-346). Among the candidate targets considered, even if with different score values (see legend to Figure 4 ), Bmf (Bcl-2-modifying factor) was predicted to be a common target for all miRNAs analyzed. In the 3 0 -untranslated region (3 0 -UTR) of Bmf two recognition sites are predicted for miR-34c-5p, one at position 737 --765 and one at position 2283 --2311 (Diana-microT 3 ) (Figure 4a ). Therefore, we determined whether Bmf might be a direct target of miR-34c-5p. As shown in Figure 4b , transfecting miR-34c-5p either in A549-FK or in parental A549 cells resulted in a decrease of Bmf protein level (of approximately 60%). Furthermore, in two miR-34c-infected cell clones analyzed, that overexpress miR-34c-5p either alone (Cl-T) or in combination with other miRNAs (Cl-K), the levels of Bmf are reduced as compared with parental A549-FK cells (Figure 4c) . Conversely, by using specific LNA-based inhibitors to antagonize miR-34c (either -5p and -3p) in Cl-T, we rescued the expression of Bmf (Figure 4d ). To prove a direct interaction between miR-34c-5p and Bmf mRNA, two Bmf 3-UTR sequences (Bmf S1 and Bmf S2), which include each of the two potential target sites for miR-34c-5p, were fused downstream from the luciferase gene. The two constructs containing either Bmf S1 or Bmf S2, either individually or in combination, were co-transfected into MEG01 cells together with miR-34c-5p or a scrambled miRNA as negative control. As shown in Figure 4e , luciferase activity of Bmf S2 decreased about 40% by co-trasfecting with miR-34c-5p. By contrast, the luciferase activities of both Bmf S1 and a deletion mutant of Bmf S2 are poorly affected by miR-34c-5p co-transfection. Taken together, these data indicate that miR-34c-5p may decrease Bmf expression by recognizing a binding site on its 3 0 -UTR starting at position 2283. As mentioned above, we identified Bmf as promising target for miR-34c-5p based on the assumption that common messengers should be targeted by miRNAs found in independent cell clones together with miR-34c. In order to verify this assumption, we determined whether miR-362 and miR-124 may affect Bmf levels as well. As shown, transfecting either miR-362 or miR-124 decreases Bmf levels (Figure 4f ). Further, we determined by luciferase assay whether miR-362 interacts with the predicted sites for the miR-362-5p and -3p strand in the Bmf 3 0 -UTR (Bmf S3 and S4, respectively). As shown in Figure 4g , luciferase activity of Bmf S3 was decreased to about 60% by co-trasfecting with miR-362-5p. By contrast, luciferase activity of the Bmf S3 mutant was poorly affected by miR-362-5p co-transfection. These results well support the working hypothesis that miRNAs for common targets may be preferentially selected during the functional screening.
Mechanism of action
In order to understand whether the decrease in Bmf levels by miR-34c-5p is sufficient to cause protection to apoptosis, we transfected A549-FK cells with either miR-34c-5p or with an small interfering RNA (siRNA) for Bmf and analyzed the activation of caspase-9 and -3 after forced dimerization of caspase-8. Interfering with Bmf expression by either miR-34c-5p or, even if to a lesser extent, by a Bmf-specific siRNA, protects the cells from AP20187-induced caspase activation (not shown). Further, to understand whether Bmf mediates the effects of miR-34c-5p, we silenced Bmf in the A549 cells with a specific short-hairpin RNA (shRNA) and determined the residual ability of miR-34c-5p to elicit protection 
Cell viability % AP20187 3h 10nM Where indicated, either an anti-miR-34c-5p inhibitor sequence or a corresponding scrambled sequence was transfected, and cell lysates were analyzed for caspase-3 (upper panel) and caspase-9 (lower panel) activity as measured by hydrolysis of Ac-DEVD-AFC or Ac-LEHD-AFC, respectively. The value of miR-34c-5p in Cl-T þ anti-miR-34c-5p, quantified by qt-RT --PCR and expressed as 2 -DDct , is 0.09±0.01 compared with Cl-T þ scrambled.
from paclitaxel-induced caspase-3 activation. As compared with Bmf-silenced cells, overexpression of miR-34c-5p was able to further reduce caspase-3 activation, thus indicating that Bmf does not fully mediate the protective effects of miR-34c-5p ( Figure 5a ). Intriguingly, miR-34c belongs to a family of evolutionarily conserved miRNAs (miR-34a, miR-34b and miR-34c) whose expression has been shown to be under the transcriptional control of the tumor-suppressor protein p53 and known to be implicated in the negative control of the cell cycle, senescence and apoptosis. 13 --16 Therefore, with the aim to reconcile this with the protective effect of miR-34c-5p on paclitaxel-induced apoptosis, we asked whether c-myc, a known target of miR-34c, 17 may as well participate to inhibit apoptosis. Indeed, c-myc, acting on the protein deacetylase Sirt1, regulates p53 acetylation, and thus its activity. 18 As expected, transfecting A549-FK cells with either miR-34c-5p, or with a c-myc-specific siRNA, resulted in a partial decrease of c-myc protein levels ( Figure 5b ). Interestingly, attenuation of c-myc expression protects cells from AP20187 ( Figure 5b ) and most importantly from paclitaxel-induced caspase-3 activation (Figure 5c ). In order to determine whether cmyc downregulation mediates miR-34c-induced protection, we depleted A549 cells of c-myc by transfecting a specific siRNA. As shown in Figure 5d , we found that miR-34c-5p becomes poorly efficient to further increase protection over that induced by c-myc silencing. Even though the contribution to protection of the passenger -3p strand remains to be elucidated, we show that the miR-34c-3p mimic we used may decrease the Bmf levels, but it is less effective on the regulation of c-myc levels ( Figure 5e ). Together, these results suggest that c-myc is a critical target of miR34c that may act by protecting cells from paclitaxel-induced apoptosis.
Paclitaxel is a microtubule destabilizer and cell-cycle integrity has been shown to be required for sensitization. 19, 20 We thus determined whether perturbation of c-myc levels by miR-34c-5p affects cell cycle, thus providing an explanation for resistance. As assessed by FACS (fluorescence-activated cell sorting) analysis, cell cycle is not appreciably impaired by transfection of miR-34c-5p ( Figure 5f ). Accordingly, as determined by immunoblotting, no drastic changes were observed upon transfection of miR-34c-5p, neither in cyclins B1 and D1 nor in Chk1 levels ( Figure 5g ). Similarly, induction of cyclin B1 levels by treatment with paclitaxel was not impaired by miR-34c-5p, thus indicating that resistance is unlikely attributable to an abnormal mitotic checkpoint response ( Figure 5h ). On the other hand, the levels of cyclin D1, which mediate p53-dependent cell-cycle arrest, 21 were increased by paclitaxel, whereas in the presence of miR-34c-5p such increase was impaired (Figure 5h) .
We then wondered whether transfecting miR-34c-5p may act on the activity of p53, monitoring p53 acetylation, which is essential for maximal p53-dependent apoptosis. 22 --24 As shown in Figure 6a , in untreated, exponentially growing A549 cells, the levels of acetylated p53 are very low and are strongly induced by paclitaxel treatment (24 h). Interestingly, miR-34c-5p overexpression counteracts the effects of paclitaxel by reducing the induction of acetylated p53 levels to less than two-fold over basal. The interference of miR-34c-5p on the levels of acetylated p53 is well mirrored by the corresponding decrease in the paclitaxel-induced expression of total p53. This suggests that miR34c-5p, by regulating p53 synthesis or stability, may indirectly act on its activity. To confirm that miR-34c-5p may interfere with paclitaxel-induced p53 activity, we performed luciferase assays transfecting a construct expressing the luciferase reporter gene under the transcriptional control of the p53-responsive human ubiquitin ligase MDM2 (mouse/human double minute 2) promoter. As shown in Figure 6b , miR-34c-5p overexpression abolishes the induction of p53 activity by paclitaxel as assessed by the corresponding levels of luciferase activity. Consistently, miR-34c-5p abolishes the induction of the MDM2 protein and decreases the levels of the deacetylase SIRT-1, which is in turn a known direct target of miR-34c 25 ( Figure 6c ). Therefore, in an attempt to understand how MDM2 is implicated in the attenuation of p53 response to paclitaxel, we inhibited MDM2 activity. Treatment of A549 cells with Nutlin-3, a direct inhibitor of MDM2, increases the levels of p53, likely by increasing its stability. At difference from what happens with paclitaxel-induced p53, transfecting miR-34c-5p in the absence of MDM2 did not result in attenuation of p53 (Figure 6d, upper panel) . Conversely, we show that following inhibition of MDM2, the balance between the levels of miR-34c-5p and p53 cannot be interfered by antagonizing 0 -UTRs, are transfected into MEG01 cells. Relative repression of firefly luciferase expression was standardized to a transfection control. The reporter assays were performed three times with essentially identical results. The predicted recognition site of Bmf at position 737 --765 (S1) is less conserved (only bosTau2 genome) than that at position 2283 --2311 (S2), which is conserved in bosTau2 and rat (rn4). Predicted free energies were calculated and are as follows: À15.1 kJ for Bmf S1 and À24.2 kJ for Bmf S2. (f ) A549 cells were transfected with miR-124, miR-124*, miR-362-5p, miR-362-3p or a control scrambled sequence, and Bmf protein levels were analyzed at the indicated time points by immunoblotting. Filters were hybridized with anti-a-tubulin to confirm equal loading. The blots are representative of at least three independent experiments. (g) The Bmf 3 0 -UTR contains predicted binding sites for miR-362-5p and miR-362-3p. In the figure is shown the alignment of the two seed regions of miR-362-5p (S3) and miR-362-3p (S4) with the Bmf 3 0 -UTR. The sites of target mutagenesis (deletion) are indicated by red dashes and red XXX. pGL3-Bmf luciferase constructs, containing wild-type (either for miR-362-5p and miR-362-3p) or mutated (for miR-362-5p) Bmf 3 0 -UTRs, are transfected into MEG01 cells. Relative repression of firefly luciferase expression was standardized to a transfection control. The reporter assays were performed three times with essentially identical results. Diana Lab: miTG score for Bmf (miR-34c, 5.72; miR-124, 10.89; miR-362-5p, 3; miR-362-3p, 2.11; miR-345, 5.0; miR-346, 2 miR-34c-5p with a specific LNA-based inhibitor (Figure 6d , lower panel).
As shown in Figure 6e , both cisplatin-and paclitaxel-induced activation of caspase-3 are decreased in stable A549 cells silenced for p53 (Figure 6e) . However, at difference from paclitaxel, the cisplatin-induced levels of p53 were unaffected by miR-34c-5p (Figure 6f ), thus suggesting that resistance to cisplatin might involve the way to induce p53 in these cells. Taken together, these data indicate that transfecting miR-34c-5p in the presence of a pro-apoptotic insult, such as paclitaxel, may protect cells from apoptosis likely by interfering with the levels of p53 and by tuning the levels of c-myc, and suggest that miR-34c-5p-induced p53 attenuation depends on MDM2 activity.
DISCUSSION
Signaling initiated by death receptors causes the recruitment and activation of initiator caspases (caspase-8 and caspase-10), thus triggering the activation of either intrinsic or extrinsic apoptotic pathways that ultimately lead to cell death. However, distinct multiple signaling pathways have been shown recently to be initiated by some of these receptors that rather promote the activation of pro-survival proteins such as NF-KB, protein kinase B (PKB)/Akt and MAP kinases that ultimately lead to a number of non-cytotoxic functions such as cell proliferation or inflammation. 26 In order to dissect miRNAs implicated in the pro-apoptotic pathway, we engineered an NSCLC-derived cell line to induce caspase-8-dependent cell death. By using a functional selection we identified miRNAs whose expression may protect cells from undergoing apoptosis. Eleven different miRNAs have been selected, which, if expressed, either alone or in combination, confer resistance to caspase-8 dimerization. Among these miRNAs, miR-34c revealed to be of particular interest. Indeed, miR-34c belongs to a conserved miRNA family consisting of three members: miR-34a, generated from a transcriptional unit on the human chromosome 1p36, and miR-34b and miR-34c, which are generated by processing of a bicistronic transcript from chromosome 11q23. Both transcripts have been shown to be under the direct positive control of p53 7, 8, 13, 14, 27, 28 and Elk1. 29 Several converging evidence demonstrated that miR-34 members mediate p53 action to negatively regulate the cell cycle, thus acting as 'bona fide' tumor-suppressor genes. 15, 16, 30, 31 Although exceptions exist, 32, 33 miR-34a/b/c have been consistently found to be poorly expressed in several tumor and tumor-derived cell lines. 8, 34 In apparent contradiction with its tumor-suppressive potential, here we demonstrate that forced expression of miR-34c may confer resistance to caspase-8-induced apoptosis, thus allowing the selected cell clones to survive and proliferate even in the presence of lethal doses of the caspase-8 dimerizer AP20187. Indeed, in A549-FK cells, the drug induces the activation of the mitochondrial pathway through activation of several pro-apoptotic members of the Bcl2 family, including BID, Bmf and Bax, which is clearly impaired by ectopic miR-34c. Resistance is unlikely due to the occurrence of new clonal critical mutations in the apoptotic pathway, indeed: (1) in two analyzed cell clones, Cl-K and Cl-T, caspase-8 sensitivity is restored by antagonizing miR-34c-5p action with a specific anti-miR; (2) apoptosis is readily activated by treating the same cell clones with an unrelated pro-apoptotic drug; (3) transfecting cells with an miR-34c-5p mimic protects the A549-FK cells from AP20187-induced cell death.
Furthermore, our data clearly show that protection is not restricted to the non-physiological pathway induced by the artificial caspase-8 dimerizer that we used for selection; in fact, activation of the mitochondrial pathway by paclitaxel was as well specifically impaired by miR-34c. Paclitaxel is a lead anticancer compound that prevents cell progression through mitosis, 35 , 36 causing cells to arrest and undergo apoptosis through activation of BID and caspase-9. However, even if our data indicate that miR34c acts by interfering with complete activation of the mitochondrial pathway, two observations show that its protective action is only unveiled under specific conditions. First, transfection of miR34c does not protect cells from other pro-apoptotic compounds, such as TRAIL or cisplatin; second, transfecting miR-34c has no protective effect on the more sensitive H460 NSCLC cell line, raising the question of which are the mechanisms that determine miR-34c to have opposite roles on cell survival or death. Yet, in the absence of definitive evidence on the critical players involved, it seems plausible that the action of miR-34c may depend on the balance of specific intracellular mediators of apoptosis. On the other hand, the protective action of miR-34c is not completely unexpected. Indeed, it has been shown recently that the cognate miRNA, miR-34a, may confer resistance to bortezomib-induced apoptosis by downregulating p53, and that survival and p53 downregulation depend on the expression levels of c-myc. 37 Indeed, c-myc is a key regulator of cell proliferation as its induction sustains cell proliferation and transformation. However, in concert with p53, elevated levels of c-myc may sensitize tumor cells to pro-apoptotic stimuli and promote cell death. 38 --42 In an attempt to understand which are the critical targets of miR-34c, we assumed that, given the protocol of functional selection adopted, some of these targets should be common to multiple miRNAs selected and found in combination with miR-34c (see legend to Figure 4 and text for details). Based on this assumption, we identified among genes with predicted consensus sites for miR-34c, the pro-apoptotic protein Bmf, a common target with predicted consensus binding sites for all the miRNAs analyzed. Indeed, attenuation of Bmf expression, even poorly, protects cells from caspase-8-induced apoptosis and thus is a promising target candidate of miR-34c, likely by directly targeting one of the predicted consensus sites in its 3 0 -UTR at position 2283. Further, according with recent reports that indicate c-myc as a target of miR-34a/c, 17, 29, 43 here we show that c-myc is downregulated by miR-34c-5p and that its downregulation is by itself sufficient to mediate much of the protective effects of miR-34c, thus proving that, in A549 cells, regulation of c-myc is critical to mediate survival. On the other hand, in good agreement with previous reports, 37 our results indicate that the effects of miR-34c involve, besides c-myc, the MDM2 and p53 loop. Indeed, miR-34c attenuates the paclitaxel-dependent induction of p53 by a mechanism that is unlikely determined by a decrease in the extent of p53 acetylation as the levels of the deacetylase SIRT-1 (a target of miR-34c) are as well decreased. Our results rather show that inhibiting MDM2 induces p53 expression, but induction becomes insensitive to intracellular levels of miR-34c, thus indicating that MDM2 activity could be required for attenuation. Therefore, a plausible explanation for the fact that miR-34c is unable to attenuate the levels of cisplatin-induced p53, whereas silencing of p53 confers resistance to both cisplatin and paclitaxel, may likely rely on the genotoxic action of cisplatin, which, at difference from paclitaxel, causes MDM2 inhibition. A primary way by which c-myc regulates MDM2 activity implicates regulation of the MDM2-regulatory protein, p14/Arf, which is, however, deleted in A549 cells, 44 thus making elusive in these cells the link between c-myc and MDM2 for protection by miR-34c. On the other hand, it has been shown that active p53 directly induces miR-34c expression, which in turn indirectly increases p53 activity, thus establishing a positive feedback loop leading to cell-cycle arrest. 13, 16, 25, 45 How this loop is attenuated is still unknown. In light of our results, it seems reasonable to hypothesize that increased levels of miR-34c may contribute to switch off the loop thus interfering with paclitaxel-induced cellcycle arrest.
These results can be relevant for both understanding the molecular mechanisms that govern the interplay between miR34c, p53 and c-myc to control cell proliferation and apoptosis, and for development of targeted, specific new therapeutic agents.
MATERIALS AND METHODS
Cell cultures
Human NSCLC A549 and H460 (American Type Culture Collection, Manassas, VA, USA) were grown in RPMI 1640 (Life Technologies, Karlsruhe, Germany) supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich Corp., Saint Louis, MO, USA), 2 mM L-glutamine and 100 U/ml penicillin --streptomycin. A549 cells carrying a deletion in the ARF locus, 44 A549-FK, clone Cl-K and clone Cl-T were cultured in the same medium supplemented with 5 mg/ml puromycin, whereas A549 stably silenced for p53 were cultured in medium supplemented with 1 mg/ml puromycin.
Immunoprecipitation and immunoblotting
Total cell lysates were prepared in JS buffer (50 mM Hepes (pH 7.5), 150 mM NaCl, 1% glycerol, 1% Triton X-10, 1.5 mM MgCl 2 , 5 mM EGTA, 1 mM Na3VO 4 , and protease and phosphatase inhibitors) and then boiled in sodium dodecyl sulfate/b-mercaptoethanol sample buffer. Samples weighing 40 or 30 mg were loaded onto 15 or 12% polyacrylamide gels, and proteins were separated by electrophoresis and then blotted onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA) by electrophoretic transfer. The membranes were then blocked with 5% dried milk in TBS containing 0.1% Tween-20 and incubated at 4 1C overnight with the following primary antibodies: anti-caspase 3; anti-caspase 9; anti-BID; antiBcl-Xl; anti-Bmf; anti-acetyl-p53 (Lys382); anti-cyclin D1 (Cell Signaling Technology Inc., Danvers, MA, USA); anti-procaspase 3 and anti-procaspase 9 (Abcam plc, Cambridge, UK); anti-c-myc (9E10); anti-p53 (DO-1); antiChk1 (G-4); anti-cyclin B1 (H-433); anti-SIRT1 (H-300) (Santa Cruz Biotechnology, Stockton, CA, USA); anti-a-tubulin (Sigma-Aldrich Corp.); and anti-MDM2 (mAB 2A10) (Calbiochem, Darmstadt, Germany).
For Bax activation analysis total cell lysates were, instead, prepared in 1% Chaps buffer (5 mM MgCl 2 , 137 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Chaps, 20 mM Tris --HCl (pH 7.5) and protease inhibitors). A 500-mg-weight of proteins was immunoprecipitated with an anti-Bax antibody (6A7; BD Pharmingen, San Diego, CA, USA) at 4 1C for 2 h. Immunoprecipitates were captured by protein A/G PLUS-agarose (Santa Cruz Biotechnology) in lysis buffer at 4 1C overnight. Immunoprecipitates were then recovered by centrifugation and washed three times in 1% Chaps buffer. Immunoprecipitates and total extracts (40 mg) were separated on 12% polyacrylamide gel. After sodium dodecyl sulfate --PAGE, proteins were transferred onto polyvinylidene difluoride membranes (Millipore) and then blocked with 5% dried milk in phosphate-buffered saline --0.1% Tween-20. The membranes were then incubated with primary anti-Bax (N20) (Santa Cruz Biotechnology) and a peroxidase-conjugated secondary antibodies in 10% dried milk in phosphate-buffered saline containing 0.1% Tween-20 and detected using ECL western blotting detection reagents (Amersham Bioscience, Piscataway, NJ, USA).
Cell proliferation and cell death analysis
Cells were plated in 96-well plates in triplicate and incubated at 37 1C in a 5% CO 2 incubator. AP20187 (ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA) was used at 10 nM for 3, 6 and 24 h. Cell viability was examined by MTT-Cell Titer 96 AQueous One Solution Cell Proliferation Assay (Promega BioSciences Inc., San Luis Obispo, CA, USA) according to the manufacturer's protocol. Metabolically active cells were detected by adding 20 ml of MTT to each well. After 20 min of incubation, plates were analyzed using an Absorbance Microplate Reader (ELx800; BioTek Instruments Inc, Winooski, VT, USA). Apoptosis was assessed by propidium iodide assay followed by flowcytometric analysis and caspase-3 and -9 fluorimetric assays. For propidium iodide assay, 24 h after transfection, cells were seeded in triplicate in 96-well plates at 3.6 Â 10 3 cells per well and grown overnight at 37 1C in a 5% CO 2 incubator. Then cells were treated with 10 nM AP20187 (ARIAD Pharmaceuticals Inc.) for 6 h or 100 nM paclitaxel (Sigma-Aldrich Corp.) for 24 h. The next day, analysis of DNA content by propidium iodide (SigmaAldrich Corp.) incorporation was performed in permeabilized cells by flow cytometry.
For caspase-3 and -9 fluorimetric assays, 50 mg of total cell lysates were incubated for 1 h at 37 1C with, respectively, the DEVD-AFC or LEHD-AFC substrate according to the manufacturer's protocol (BioVision Inc., Mountain View, CA, USA). After incubation, samples were read with a fluorimeter equipped with a 400-nm excitation filter and 505-nm emission filter.
For cell-cycle analysis, cells transfected with 70 nM of miRNA precursor hsa-miR-34c-5p or a scrambled molecule were recovered 48 and 72 h after transfection, fixed in 70% ethanol, stained with 50 mg/ml propidium iodide (Sigma-Aldrich Corp.) and analyzed by FACS.
Cell transfections
The day before transfection, cells were seeded in 10% fetal bovine serum medium without antibiotics. All transfections were performed using the serum-free Opti-MEM and Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. To alter miRNA level, cells were transfected with 70 nM of the miRNA precursors hsa-miR-34c-5p, hsa-miR-34c-3p, hsa-miR-124, hsa-miR-124*, hsa-miR-362-5p and hsa-miR-362-3p and negative control #1 (Ambion, Monza, Italy) or 50 nM of an LNA anti-miR-34c-5p, anti-miR-34c-3p and anti-miR negative control inhibitor (Exiqon, Woburn, MA, USA). To alter c-myc and Bmf level, cells were transfected with 60 nM siRNA c-myc (Sigma-Aldrich Corp.) and 120 nM siRNA Bmf (Santa Cruz Biotechnology).
For p53 and Bmf stable gene silencing, A549 cells were transfected in 100-mm dishes with 10 mg of shRNAp53, shRNA Bmf or shRNAcntrl (Open Biosystems, Lafayette, CO, USA). For stable clone selection, RPMI medium supplemented with 1 mg/ml puromycin was used.
Luciferase assays
For target validation the two Bmf 3 0 -UTR sequences were PCR-amplified using the following primers: Bmf S1 Fw: 5 0 -CTAGAAGGATTCCTGGCC AGCTCCT-3 0 , Bmf S1 0 . The megakaryoblastic cell line, MEG01, as widely used efficient recipient, was used for luciferase assays. Cells were co-transfected with 1.2 mg each of a generated plasmid and 400 ng of a Renilla luciferase expression construct pRL-TK (Promega BioSciences Inc.) with Lipofectamine 2000 (Invitrogen). Cells were harvested 24 h after transfection and assayed by Dual Luciferase Assay (Promega BioSciences Inc.) according to the manufacturer's instructions. Three independent experiments were performed in triplicate.
For p53 promoter activity analysis, cells were transfected using Lipofectamine 2000 (Invitrogen) with 500 ng of the pLuc-MDM2 expression vector (kindly provided by S Soddu), 900 ng of the miRNA precursor hsamiR-34c-5p or negative control #1 (Ambion), together with 40 ng of pCMVRenilla in six-well plates. Luciferase and Renilla activity were assessed using a Luciferase assay system and a Renilla Luciferase assay system (Promega BioSciences Inc.) 48 h after transfection. Luciferase activity was normalized to Renilla activity. All experiments were performed three times in triplicate and mean±s.d. was reported.
qt-RT --PCR analysis
The reverse transcription reaction was performed starting with 1 mg of total RNA and using the miScript Reverse Transcription kit (Qiagen, Milan Italy) according to the manufacturer's protocol. The expression of mature hsamiR-34c-5p, has-miR-34c-3p, hsa-miR-362-5p, hsa-miR-362-3p, hsa-miR-124 and hsa-miR-124*, and U6 RNA, as housekeeping gene, was assayed using the miScript SYBR Green PCR kit (Qiagen) and real-time PCR was performed in triplicate for each case. miRNA expression was measured using C t (threshold cycle). The DDC t method for relative quantization of gene expression was used to determine miRNA expression levels. DC t was calculated by subtracting the C t of U6 RNA from the C t of the miRNA of interest. DDC t was calculated by subtracting the DC t of the reference sample (A549-FK cells not transduced with miRNAs) from the DC t of each sample. Fold change was generated using the equation 2
ÀDDCt .
